Results 1 to 10 of about 92,915 (120)

Mechanisms of Reactivation and Its Interaction with [PDF]

Endocrinology and Metabolism, 2020
The telomerase reverse transcriptase (TERT) gene, which is repressed in most differentiated human cells, can be reactivated by somatic TERT alterations and epigenetic modulations.
Young Shin Song, Young Joo Park
doaj   +1 more source

Correlation between KRAS, NRAS and BRAF mutations and tumor localizations in patients with primary and metastatic colorectal cancer

Archives of Medical Science, 2021
Introduction Detection of abnormalities in the KRAS, NRAS and BRAF genes is extremely important for proper qualification of colorectal cancer (CRC) patients for therapy with anti-EGFR (epidermal growth factor receptor) monoclonal antibodies.
Aleksandra Bożyk, Paweł Krawczyk, Katarzyna Reszka, Kinga Krukowska, Agnieszka Kolak, Sławomir Mańdziuk, Kamila Wojas-Krawczyk, Rodryg Ramlau, Janusz Milanowski   +8 more
doaj   +1 more source

Molecular selection of therapy in metastatic colorectal cancer: the FOCUS4 molecularly stratified RCT

Efficacy and Mechanism Evaluation, 2022
Background: Complex trials with innovative designs are becoming increasingly common and offer the potential to improve patient outcomes in a shorter time frame.
Louise C Brown, David Fisher, Richard Adams, Jenny Seligmann, Matthew Seymour, Richard Kaplan, Susan D Richman, Philip Quirke, Rachel Butler, Helen Roberts, Janet Graham, Richard H Wilson, Timothy S Maughan   +12 more
doaj   +1 more source

Clinicopathological relevance of BRAF and SMO mutations in Chinese patients with ameloblastoma

All Life, 2023
Ameloblastomas are benign tumors associated with recurrence and morbidity. Mutations in the V-Raf murine sarcoma viral oncogene homolog B1 (BRAF) and smoothened (SMO) genes have been identified in ameloblastomas.
Chen Ruixue, Li Hexiang, Hou Yali, Li Xiangjun, Sun Xu, Wang Jie, Zhang Xudong   +6 more
doaj   +1 more source

Study on relationship between genetic abnormalities and clinicopathological features in K hospital's patients with colorectal cancer

Journal of Advanced Biotechnology and Experimental Therapeutics, 2022
The MAPK-ERK, as well as PI3K-AKT signaling transduction pathway, represents a pivotal function in tumorigenesis. Genetic alterations of potential tumor-driven genes, for instance, KRAS, BRAF, NRAS, and PIK3CA can result in uncontrolled cell ...
Linh Dieu Vuong, Ha Hoang Chu, Quang Ngoc Nguyen   +2 more
doaj   +1 more source

Immunological effects of BRAF+MEK inhibition

OncoImmunology, 2018
Recent developments in immunotherapy have prolonged overall survival in metastatic melanoma with the possibility to reach a long-term benefit. Targeted therapies based on BRAF and MEK inhibition also seem to have a long-term beneficial effect, which is ...
Paolo A. Ascierto, Reinhard Dummer
doaj   +1 more source

DETECTION OF SOMATIC MUTATIONS IN THE BRAF GENE BY PYROSEQUENCING

Сибирский онкологический журнал, 2021
Introduction. Detection of somatic mutations in the BRAF gene can be used in clinical oncology to clarify the diagnosis, select therapy and assess the prognosis of the disease.
O. P. Dribnokhodova, E. A. Dunaeva, G. V. Leshkina, E. A. Yarygina, A. Yu. Bukharina, Ya. A. Voiciehovskaya, E. V. Borisova, S. K. Bormotova, A. I. Daoud, V. N. Khlavich, K. O. Mironov   +10 more
doaj   +1 more source

Oncogenic BRAF mutation induces DNA methylation changes in a murine model for human serrated colorectal neoplasia

Epigenetics, 2018
Colorectal cancer is a major cause of cancer death and approximately 20% arises within serrated polyps, which are under-recognized and poorly understood.
Catherine E. Bond, Cheng Liu, Futoshi Kawamata, Diane M. McKeone, Winnie Fernando, Saara Jamieson, Sally-Ann Pearson, Alexandra Kane, Susan L. Woods, Tamsin R. M. Lannagan, Roshini Somashekar, Young Lee, Troy Dumenil, Gunter Hartel, Kevin J. Spring, Jennifer Borowsky, Lochlan Fennell, Mark Bettington, Jason Lee, Daniel L. Worthley, Barbara A. Leggett, Vicki L. J. Whitehall   +21 more
doaj   +1 more source

Deep and lasting response and acquired resistance to BRAFV600E targeting in a low-grade ovarian cancer patient

Cancer Biology & Therapy, 2023
The treatment of BRAFV600E mutant melanoma has been revolutionized by BRAF inhibitors. Furthermore, the BRAF/MEK combination has shown further improvement in clinical outcomes in advanced and in adjuvant melanoma patients.
Sandro Anchisi, Anita Wolfer, Bettina Bisig, Edoardo Missiglia, Amine Tiab, Ehab Mohamed Kamel, Olivier Michielin, George Coukos, Krisztian Homicsko   +8 more
doaj   +1 more source

KRAS and BRAF Concomitant Mutations in a Patient with Metastatic Colon Adenocarcinoma: An Interesting Case Report

Case Reports in Oncology, 2020
A 68-year-old female patient with tenesmus and blood in the stool was admitted to the S.G. Moscati Hospital of Taranto. Investigations revealed infiltrative mucinous colon adenocarcinoma accompanied by lymph node metastases.
Concetta Cafiero, Agnese Re, Gerardo D’Amato, Pier Luigi Surico, Giammarco Surico, Michele Pirrelli, Salvatore Pisconti   +6 more
doaj   +1 more source